Skip to main content
REMEVi
ENES
What REMEVi offers

Epitalon side effects: what is reported and what is unknown

Human studies, animal and lab studies, and the gaps between them.

Small Russian human studies of Epitalon reported few adverse effects, but they were not built to detect them, and no dedicated human safety study exists. Lab work on telomerase raised a cancer-related question that FDA’s 2026 review said current data cannot settle. Epitalon is not FDA-approved, and REMEVi does not currently offer it.

Epitalon is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.

REMEVi does not currently offer Epitalon.

Reported in human studies

  • A small study of older adults given Epitalon by injection for 10 days reported “no apparent adverse effects,” but how adverse events were collected was limited.
  • An under-the-tongue study in women did not report adverse events systematically.
  • A retinitis pigmentosa study described no treatment-related complications.

A 2026 review concluded that human safety data for Epitalon are minimal and that no dedicated prospective human safety study exists. Absence of reported side effects in small studies is not evidence that there are none.

Reported in animal and lab studies

  • In a 2025 cell study, Epitalon lengthened telomeres in normal human cells and, through a different pathway (ALT), in breast cancer cell lines.
  • FDA’s 2026 review flagged telomerase activation and telomere lengthening as a potential cancer-related concern and found the nonclinical data too limited to characterize it.
  • FDA staff also raised immunogenicity questions, meaning whether the body may react to the peptide or its impurities.
  • Mouse studies of tumor development exist, but animal findings do not show what happens in people.

What is unknown

  • Long-term effects of repeated courses in people.
  • How Epitalon is absorbed, distributed and cleared in humans (pharmacokinetics).
  • Which dose, if any, is appropriate; there are no dose-ranging studies.
  • Interactions with other medicines.
  • Effects in pregnancy, breastfeeding, children and teens.

Injection-site effects

As with any injection, redness, swelling, bruising, itching or soreness where the needle went in are possible. A product that is not sterile raises the risk of infection, which is one reason the policy requires a licensed 503A pharmacy and a documented bulk source. Tell your provider about a reaction that spreads, hardens, gets hotter or does not settle.

Call 911 for signs of a severe allergic reaction, such as trouble breathing, swelling of the face or throat, or hives over the body.

Who should not use Epitalon without a provider’s review

  • Anyone pregnant, trying to become pregnant or breastfeeding: no data exist.
  • Anyone under 18.
  • Anyone with active cancer or a history of cancer: tell your provider, given the open telomerase question.
  • Anyone with a known allergy to Epitalon or to any ingredient in the product.
  • Anyone taking other medicines or supplements: tell your provider about all of them.

Is Epitalon safe?

There is not enough human evidence to answer that. Epitalon is not FDA-approved, the human studies were small and not designed to find side effects, and FDA’s 2026 review raised cancer-related and immunogenicity questions it could not resolve. A licensed provider can weigh what is known against your own history before any decision.

Report a side effect

You or your provider can report a side effect to FDA MedWatch. Under the HHS policy, serious adverse events from a covered compounded product must be reported to MedWatch.

FDA MedWatch: report a problem

Sources

  1. Jain et al., Int J Mol Sci 2026 — Epitalon and Epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence (read November 2, 2026)
  2. Al-Dulaimi et al., Biogerontology 2025 — Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (read November 2, 2026)
  3. Khavinson et al., Neuro Endocrinol Lett 2002 — Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa (read November 2, 2026)
  4. Kossoy et al., In Vivo 2006 — Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice (read November 2, 2026)
  5. FDA — MedWatch: The FDA Safety Information and Adverse Event Reporting Program (read November 2, 2026)
  6. HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Federal Register, October 30, 2026) (read November 2, 2026)
  7. Foley & Lardner, National Law Review 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)

Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·